ClinicalTrials.gg
CompletedNCT01393106Updated Nov 19, 2018Results posted

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

A Phase 2 interventional study of Idelalisib in Hodgkin Lymphoma, sponsored by Gilead Sciences. Completed at 3 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.

Enrollment
503rd of 818
25 · median 35
Started
2011
with 38 others
Phase 2
346 of 970
30 open now
Registered
585th of 970
by date

Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 503rd largest by enrollment of the 818 interventional ones that give a count, is one of 39 that started in 2011, is one of 346 in phase 2, and was the 585th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 970 studies in Hodgkin Disease with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of idelalisib in participants with relapsed of refractory Hodgkin Lymphoma (HL). The primary objective will be to assess the overall response rate.

Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg twice daily. Treatment with idelalisib will continue until tumor progression or unacceptable toxicity.

03

Conditions studied

  • Hodgkin Lymphoma

Browse trials for

Keywords

  • HL
  • idelalisib
  • CAL-101
  • GS-1101
  • PI3K
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 12 years
  • performance score of ≥ 60 ( (ECOG) performance score of 0, 1, or 2)
  • confirmed diagnosis of classic HL (ie, nodular sclerosis, mixed cellularity, lymphocyte depleted, and or lymphocyte rich types)
  • Nodal HL that shows fluorodeoxyglucose (FDG) avidity (defined as focal or diffuse FDG uptake above background in a location incompatible with normal anatomy or physiology), and is measurable (defined as the presence of ≥ 1 nodal lesion that measures ≥ 2 cm in a single dimension as assessed by CT, PET/CT, or magnetic resonance imaging (MRI))
  • HL after prior myeloablative therapy with stem cell transplantation (ASCT) or after ≥ 2 prior chemotherapy-containing regimens and no curative option with conventional therapy
  • Discontinuation of all radiotherapy or chemotherapy for the treatment of HL greater than or equal to 3 weeks before initiation of study treatment and discontinuation of all radioimmunotherapy for HL (Visit 2)
  • All acute toxic effects (excluding alopecia, neurotoxicity, or anemia) of any prior antitumor therapy resolved to Grade ≤ 2 before initiation of study treatment (Visit 2)
  • For men and women of willingness to abstain from sexual intercourse or employ an effective method of during the study drug administration and follow-up periods
  • Willingness and ability to provide written and to comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Known active central nervous system or lymphoma
  • History of a non-lymphoma except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localized prostate cancer, other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for ≥ 5 years
  • Evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment (Visit 2)
  • Pregnancy or breastfeeding
  • Ongoing alcohol or drug addiction
  • Known history of drug-induced liver injury, chronic active virus (HCV), chronic active virus (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver or portal hypertension
  • History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  • Ongoing therapy, including systemic .
  • Prior therapy with idelalisib
  • Exposure to another drug within 3 weeks prior to start of study treatment
  • Concurrent participation in another therapeutic treatment trial
  • Prior or ongoing illness, medical condition, surgical history, physical finding, finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the patient; alter the absorption, distribution, metabolism or excretion of the study drug; or impair the assessment of study results
  • Prior therapy with any drug that inhibits Akt, Bruton tyrosine kinase (BTK), Janus kinase (JAK), mammalian target of rapamycin (mTOR), phosphatidylinositol 3 kinase (PI3K) (including idelalisib), or spleen tyrosine kinase (SYK)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Idelalisib

    Participants will receive up to 300 mg of idelalisib twice daily.

    Drug: Idelalisib

Interventions

  • Idelalisib tablets administered orally

    Also known as: Zydelig®, GS-1101, CAL-101

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as assessed by the investigator. * CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. * PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions.

    Time frame: Up to Week 110

Secondary outcomes

  1. Duration of Response

    Duration of response (DOR) was defined as the interval from the first documentation of PR or CR to the earlier of the first documentation of disease progression or death from any cause.

    Time frame: Up to Week 110

  2. Percent Change From Baseline in the Sum of the Product of the Greatest Perpendicular Diameters (SPD) of Target Lymph Nodes as Documented Radiographically

    Time frame: Baseline, Week 8, Week 48, and up to Week 110

  3. Change From Baseline in Fluorodeoxyglucose (FDG) Uptake in Lymph Nodes as Assessed by Positron-emission Tomography (PET)

    Time frame: Up to Week 110

  4. Time to Response

    Time to response (TTR) was defined as the interval from the start of idelalisib treatment to the first documentation of CR or PR.

    Time frame: Up to Week 110

  5. Overall Survival

    Overall survival was defined as the time from start of idelalisib treatment to death from any cause.

    Time frame: Up to Week 110

  6. Progression Free Survival

    Progression free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression or death from any cause.

    Time frame: Up to Week 110

  7. Time to Treatment Failure

    Time to treatment failure (TTF) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression, the permanent cessation of idelalisib therapy due to an adverse event, or death from any cause.

    Time frame: Up to Week 110

  8. Changes in Health-related Quality of Life as Reported Using the Functional Assessment of Cancer Therapy: Lymphoma (FACT-Lym) Questionnaire

    Change in health-related quality of life was reported by participants using the FACT-Lym questionnaire assessment tool. Results are presented as the mean (SD) best change from baseline in FACT-Lym total score, which was defined as the highest change score (improvement) after baseline. The FACT-Lym total score is on a scale from 0-168, with higher scores associated with a better quality of life.

    Time frame: Baseline and up to Week 110

  9. Changes in Performance Status as Documented Using the Karnofsky Performance Criteria for Participants ≥ 16 Years of Age and the Lansky Performance Criteria for Participants < 16 Years of Age

    Changes in performance status were assessed using the Karnofsky performance criteria for participants ≥ 16 years of age and the Lansky performance criteria for participants \< 16 years of age. Since there were no participants \< 16 years of age, only the Karnofsky performance criteria were used. The change in Karnofsky performance status was reported as the best (highest change score) and worst (lowest change score) change from baseline using the Karnofsky performance criteria. The Karnofsky score classifies patients according to their functional impairment. Scores are on a scale from 0-100, the lower the score, the worse the survival for most serious illnesses.

    Time frame: Baseline and up to Week 110

  10. Changes in the Plasma Concentrations of Disease-associated Chemokines and Cytokines

    Time frame: Up to Week 110

  11. Overall Safety Profile of Idelalisib

    The overall safety of idelalisib was assessed as the percentage of participants experiencing adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib), clinically significant abnormal electrocardiograms (ECG), and laboratory abnormalities. "Clinically significant" abnormalities in ECG were as determined by the investigator.

    Time frame: Up to Week 110

  12. Compliance With Study Drug Dosing as Assessed by Accounting for Used and Unused Drug

    Time frame: Up to Week 110

  13. Idelalisib Trough and Peak Plasma Concentration at Week 4

    Plasma samples were collected predose (trough) and 1.5 hours postdose (peak). The minimum and maximum value among participants sampled at each time point are presented. Results of less than the lower limit of quantitation (ie, 5 ng/mL) were treated as zero prior to the achievement of the first quantifiable concentration and as missing otherwise.

    Time frame: Predose and 1.5 hours postdose at Week 4

07

Results

Posted Dec 24, 2015
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 15 September 2011. The last study visit occurred on 28 August 2014.

Participant flow — Overall Study
MilestoneIdelalisib
Started25
Completed20
Not completed5
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1
Withdrew: Lack of efficacy1

Outcome measures

PrimaryOverall Response Rate

Overall response rate (ORR) was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as assessed by the investigator. * CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. * PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions.

Time frame:
Up to Week 110
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsIdelalisib
Overall Response Rate20.0 (6.8 to 40.7)
SecondaryDuration of Response

Duration of response (DOR) was defined as the interval from the first documentation of PR or CR to the earlier of the first documentation of disease progression or death from any cause.

Time frame:
Up to Week 110
Reported as:
Median · months
Duration of Response
monthsIdelalisib
Duration of Response8.4 (1.8 to NA)
SecondaryPercent Change From Baseline in the Sum of the Product of the Greatest Perpendicular Diameters (SPD) of Target Lymph Nodes as Documented Radiographically
Time frame:
Baseline, Week 8, Week 48, and up to Week 110
Reported as:
Median · percent change in SPD
Percent Change From Baseline in the Sum of the Product of the Greatest Perpendicular Diameters (SPD) of Target Lymph Nodes as Documented Radiographically
percent change in SPDIdelalisib
Percent Change at Week 8 (n = 24)-14.1 (-73.1 to 112.5)
Percent Change at Week 48 (n = 5)-45.9 (-92.6 to 7.8)
Best Percent Change from Baseline (n = 24)-24.1 (-92.6 to 112.5)
SecondaryChange From Baseline in Fluorodeoxyglucose (FDG) Uptake in Lymph Nodes as Assessed by Positron-emission Tomography (PET)
Time frame:
Up to Week 110

No measurements were reported for this outcome.

SecondaryTime to Response

Time to response (TTR) was defined as the interval from the start of idelalisib treatment to the first documentation of CR or PR.

Time frame:
Up to Week 110
Reported as:
Median · months
Time to Response
monthsIdelalisib
Time to Response2.0 (1.9 to 16.8)
SecondaryOverall Survival

Overall survival was defined as the time from start of idelalisib treatment to death from any cause.

Time frame:
Up to Week 110
Reported as:
Median · months
Overall Survival
monthsIdelalisib
Overall Survival19.8 (12.3 to NA)
SecondaryProgression Free Survival

Progression free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression or death from any cause.

Time frame:
Up to Week 110
Reported as:
Median · months
Progression Free Survival
monthsIdelalisib
Progression Free Survival2.3 (1.8 to 3.7)
SecondaryTime to Treatment Failure

Time to treatment failure (TTF) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression, the permanent cessation of idelalisib therapy due to an adverse event, or death from any cause.

Time frame:
Up to Week 110

No measurements were reported for this outcome.

SecondaryChanges in Health-related Quality of Life as Reported Using the Functional Assessment of Cancer Therapy: Lymphoma (FACT-Lym) Questionnaire

Change in health-related quality of life was reported by participants using the FACT-Lym questionnaire assessment tool. Results are presented as the mean (SD) best change from baseline in FACT-Lym total score, which was defined as the highest change score (improvement) after baseline. The FACT-Lym total score is on a scale from 0-168, with higher scores associated with a better quality of life.

Time frame:
Baseline and up to Week 110
Reported as:
Mean · units on a scale
Changes in Health-related Quality of Life as Reported Using the Functional Assessment of Cancer Therapy: Lymphoma (FACT-Lym) Questionnaire
units on a scaleIdelalisib
Changes in Health-related Quality of Life as Reported Using the Functional Assessment of Cancer Therapy: Lymphoma (FACT-Lym) Questionnaire5.1 ± 7.24
SecondaryChanges in Performance Status as Documented Using the Karnofsky Performance Criteria for Participants ≥ 16 Years of Age and the Lansky Performance Criteria for Participants < 16 Years of Age

Changes in performance status were assessed using the Karnofsky performance criteria for participants ≥ 16 years of age and the Lansky performance criteria for participants \< 16 years of age. Since there were no participants \< 16 years of age, only the Karnofsky performance criteria were used. The change in Karnofsky performance status was reported as the best (highest change score) and worst (lowest change score) change from baseline using the Karnofsky performance criteria. The Karnofsky score classifies patients according to their functional impairment. Scores are on a scale from 0-100, the lower the score, the worse the survival for most serious illnesses.

Time frame:
Baseline and up to Week 110
Reported as:
Mean · units on a scale
Changes in Performance Status as Documented Using the Karnofsky Performance Criteria for Participants ≥ 16 Years of Age and the Lansky Performance Criteria for Participants < 16 Years of Age
units on a scaleIdelalisib
Best Change6 ± 5.3
Worst Change-1 ± 6.9
SecondaryChanges in the Plasma Concentrations of Disease-associated Chemokines and Cytokines
Time frame:
Up to Week 110

No measurements were reported for this outcome.

SecondaryOverall Safety Profile of Idelalisib

The overall safety of idelalisib was assessed as the percentage of participants experiencing adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib), clinically significant abnormal electrocardiograms (ECG), and laboratory abnormalities. "Clinically significant" abnormalities in ECG were as determined by the investigator.

Time frame:
Up to Week 110
Reported as:
Number · percentage of participants
Overall Safety Profile of Idelalisib
percentage of participantsIdelalisib
Any AE96.0
Serious AE36.0
Grade ≥ 3 AE48.0
AE related to idelalisib76.0
AE leading to permanent drug discontinuation8.0
Clinically significant abnormal ECG at Week 160
Grade 3 or 4 hemoglobin4.0
Grade 3 or 4 neutrophils8.0
Grade 3 or 4 platelets4.0
Grade 3 or 4 alanine aminotransferase20.0
Grade 3 or 4 aspartate aminotransferase16.0
SecondaryCompliance With Study Drug Dosing as Assessed by Accounting for Used and Unused Drug
Time frame:
Up to Week 110
Reported as:
Mean · number of doses
Compliance With Study Drug Dosing as Assessed by Accounting for Used and Unused Drug
number of dosesIdelalisib
Number of doses dispensed463 ± 462.3
Number of doses taken329 ± 321.1
SecondaryIdelalisib Trough and Peak Plasma Concentration at Week 4

Plasma samples were collected predose (trough) and 1.5 hours postdose (peak). The minimum and maximum value among participants sampled at each time point are presented. Results of less than the lower limit of quantitation (ie, 5 ng/mL) were treated as zero prior to the achievement of the first quantifiable concentration and as missing otherwise.

Time frame:
Predose and 1.5 hours postdose at Week 4
Reported as:
Number · ng/mL
Idelalisib Trough and Peak Plasma Concentration at Week 4
ng/mLIdelalisib
Trough - minimum (n = 20)142
Trough - maximum (n = 20)2120.0
Peak - minimum (n = 22)90.2
Peak - maximum (n = 22)8570.0

Adverse events

Collected over Up to Week 110. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib—9/25 (36%)24/25 (96%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventIdelalisib
Rash maculo-papularSkin and subcutaneous tissue disorders2/25
Febrile neutropeniaBlood and lymphatic system disorders1/25
ColitisGastrointestinal disorders1/25
VomitingGastrointestinal disorders1/25
PyrexiaGeneral disorders1/25
Herpes zosterInfections and infestations1/25
Lung infectionInfections and infestations1/25
PneumoniaInfections and infestations1/25
Skin infectionInfections and infestations1/25
Platelet count decreasedInvestigations1/25
Most frequent other events
Showing 10 of 35
Most frequent other events
EventIdelalisib
FatigueGeneral disorders8/25
ConstipationGastrointestinal disorders6/25
VomitingGastrointestinal disorders6/25
PyrexiaGeneral disorders6/25
Aspartate aminotransferase increasedInvestigations6/25
ChillsGeneral disorders5/25
Alanine aminotransferase increasedInvestigations5/25
CoughRespiratory, thoracic and mediastinal disorders5/25
LeukopeniaBlood and lymphatic system disorders4/25
NeutropeniaBlood and lymphatic system disorders4/25

Baseline characteristics

Intent-to-treat (ITT) Analysis Set: participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Idelalisib
Mean43 ± 16.1
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib
Female14
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Idelalisib
Asian1
Black or African American2
White19
Other3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Idelalisib
Hispanic or Latino3
Not Hispanic or Latino22
Time Since Diagnosis (years)
Time Since Diagnosis (years)(years)Idelalisib
Mean3.9 ± 4.26
Classical Hodgkin Lymphoma Pathologic Subtype
Classical Hodgkin Lymphoma Pathologic Subtype(participants)Idelalisib
Nodular Sclerosis23
Lymphocyte Rich2
Disease Stage at Screening
Disease Stage at Screening(participants)Idelalisib
Stage I1
Stage II8
Stage III6
Stage IV10
Karnofsky Performance Status
Karnofsky Performance Status(units on a scale)Idelalisib
Mean83 ± 7.1
08

Study locations

3 sites
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Gopal AK, Fanale MA, Moskowitz CH, Shustov AR, Mitra S, Ye W, Younes A, Moskowitz AJ. Phase II study of idelalisib, a selective inhibitor of PI3Kdelta, for relapsed/refractory classical Hodgkin lymphoma. Ann Oncol. 2017 May 1;28(5):1057-1063. doi: 10.1093/annonc/mdx028. PubMed 28327905 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 13, 2011
Start
Sep 2011
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Dec 24, 2015
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01393106
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Sep 2011
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Dec 24, 2015
Last update
Nov 19, 2018

Study contacts

Lyndah Dreiling, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion